The A4 study is recruiting older adults ages 65 to 85 with no outward signs of dementia to participate in a landmark prevention trial.
Physicians and researchers will use an imaging test to determine whether a potential participant has evidence of elevated amyloid plaque buildup in their brains. People with elevated levels will be eligible to participate in the study, which will involve trials of the investigational drug and a placebo, as well as regular thinking and memory tests.
The A4 study, coordinated by the Alzheimer's Disease Cooperative Study, is a public-private partnership funded by the National Institute on Aging, Eli Lilly and Company, and a number of philanthropic organizations.
Dr. Penny Dacks was previously the Director of Aging and Alzheimer’s Disease Prevention at the Alzheimer's Drug Discovery Foundation. She was trained in neuroscience at the Mount Sinai School of Medicine, the University of Arizona, and Queen's University (Canada) with individual fellowships from the National Institute of Health, the Evelyn F. McKnight Brain Research Foundation, the ARCS Foundation and the Hilda and Preston Davis Foundation. She has authored over 18 peer-reviewed scientific articles and is a member of the Society for Neuroscience, the Gerontological Society of America, the Endocrine Society and the Association for Women in Science.
Get the latest brain health news: